1. MAPK/ERK Pathway
  2. MEK

MEK

MEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK). The activators of p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways. The acronym MEK derives from Mitogen/Extracellular signal-regulated Kinase. MEK is a member of the MAPK signaling cascade that is activated in melanoma. When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced.

MEK Related Products (28):

Cat. No. Product Name Effect Purity
  • HY-12031
    U0126 Inhibitor 98.03%
    U0126 is a non-ATP competitive MEK inhibitor, with IC50 of 70 nM and 60 nM for MEK1 and MEK2, respectively.
  • HY-10999
    Trametinib Inhibitor 99.37%
    Trametinib is a potent MEK1/2 inhibitor that specifically inhibits MEK1/2, with an IC50 value of about 2 nM.
  • HY-12028
    PD98059 Inhibitor 99.45%
    PD98059 is a MEK inhibitor with IC50 of 5 μM, also suppresses TCDD binding to the aryl hydrocarbon receptor (AHR) with IC50 of 4 μM.
  • HY-10254
    PD0325901 Inhibitor 99.95%
    PD0325901 (PD325901) is selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM.
  • HY-50706
    Selumetinib Inhibitor 99.39%
    Selumetinib is a highly potent MEK inhibitor, with an IC50 value of 14 nM against MEK1.
  • HY-13064A
    Cobimetinib hemifumarate Inhibitor 99.27%
    Cobimetinib hemifumarate is a novel selective MEK inhibitor, and the IC50 value against MEK1 is 4.2 nM.
  • HY-13064
    Cobimetinib Inhibitor 98.79%
    Cobimetinib is a novel selective MEK inhibitor, and the IC50 value against MEK1 is 4.2 nM.
  • HY-10999A
    Trametinib DMSO solvate Inhibitor 98.53%
    Trametinib DMSO solvate is a potent MEK1/2 inhibitor that specifically inhibits MEK1/2, with an IC50 value of about 2 nM.
  • HY-15202
    MEK162 Inhibitor 98.61%
    MEK162 is a potent and selective mitogen-activated protein kinase (MEK) inhibitor wirh IC50 of 12 nM.
  • HY-50295
    CI-1040 Inhibitor 99.72%
    CI-1040 (PD184352) is an orally active, highly specific, small-molecule inhibitor of MEK with an IC50 of 17 nM for MEK1.
  • HY-12467
    OTS-964 Inhibitor 98.08%
    OTS964 is a potent TOPK inhibitor with an IC50 value of 28 nM.
  • HY-14691
    Refametinib Inhibitor 98.46%
    Refametinib (RDEA119, BAY 86-9766), is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity (IC50=19 nM MEK1; IC50=47 nM MEK2).
  • HY-13449
    TAK-733 Inhibitor 99.74%
    TAK-733 is a potent and selective MEK allosteric site inhibitor for MEK1 with IC50 of 3.2 nM, inactive to Abl1, AKT3, c-RAF, CamK1, CDK2, c-Met, etc.
  • HY-18652
    Ro 5126766 Inhibitor >98.0%
    Ro 5126766 (CH5126766) is a potent and selective dual RAF/MEK inhibitor. For SK-MEL-28, SK-MEL-2, MIAPaCa-2, and SW480 cell lines, the IC50 is determined by WST-8 assay is 65, 28, 40, and 46 nM, respectively.
  • HY-12042
    AS703026 Inhibitor
    AS703026 is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2, used for cancer treatment.
  • HY-15610
    GDC-0623 Inhibitor
    GDC-0623 is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC50=42 nM) versus A375 (BRAFV600E, EC50=7 nM).
  • HY-15437
    SL327 Inhibitor >98.0%
    SL-327 is a cell-permeable vinylogous cyanamide that acts as a selective inhibitor of MEK-1 and MEK-2 (IC50 = 0.18 and 0.22 μM respectively).
  • HY-12058
    AZD8330 Inhibitor
    AZD8330(ARRY-424704; ARRY-704) is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM.
  • HY-12056
    BIX02189 Inhibitor 99.65%
    BIX02189 is a selective MEK5/ERK5 inhibitor with an IC50 of 59 nM.
  • HY-14719
    RO4987655 Inhibitor 98.22%
    RO4987655(CH-4987655) is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1/MEK1 IC50=5.2 nM), with potential antineoplastic activity.